Find, compare & contact
Acido risedronico (Risedronate) API Manufacturers & Suppliers

Looking for Risedronate API 105462-24-6?

Description:

Here you will find a list of producers, manufacturers and distributors of Risedronate. You can filter on certificates such as GMP, FDA, CEP, Written Confirmation and more. Send inquiries for free and get in direct contact with the supplier of your choice.

API | Excipient name:

Risedronate 

Synonyms:

Acido risedronico , Acidum risedronicum , Ridron , Risedronate , Risedronic acid , Risedronate sodium 2.5-hydrate  

Cas Number:

105462-24-6 

DrugBank number:

DB00884 

Unique Ingredient Identifier:

KM2Z91756Z

Risedronate is a type of Bisphosphonates

Bisphosphonates are a vital subcategory of pharmaceutical active pharmaceutical ingredients (APIs) widely used in the treatment of various bone-related conditions. These compounds play a crucial role in inhibiting bone resorption, making them particularly effective in managing diseases such as osteoporosis, Paget's disease, and bone metastasis associated with cancer.

The mechanism of action of bisphosphonates involves their binding to hydroxyapatite crystals in bone, leading to the suppression of osteoclast activity. By inhibiting the breakdown of bone tissue, these APIs help to maintain bone density and strength, thereby reducing the risk of fractures and improving overall bone health.

One of the key advantages of bisphosphonates is their high affinity for bone tissue, which allows for targeted treatment. They are administered orally or intravenously, depending on the specific formulation and indication. Commonly prescribed bisphosphonates include alendronate, ibandronate, and zoledronic acid, among others.

Bisphosphonates are generally well-tolerated, although some potential side effects, such as gastrointestinal disturbances or musculoskeletal pain, may occur. These APIs are metabolized in the liver and excreted through the kidneys.

Due to their effectiveness and widespread clinical use, bisphosphonates have gained significant attention in the pharmaceutical industry. Continuous research and development efforts are focused on improving their therapeutic profiles, including enhancing potency and reducing side effects.

In summary, bisphosphonates are a critical subcategory of pharmaceutical APIs employed in the management of bone-related disorders. Their targeted action on bone tissue and ability to inhibit bone resorption make them indispensable in the treatment of conditions like osteoporosis and bone metastasis. Ongoing advancements in this field are expected to further optimize their therapeutic benefits in the future.

Risedronate (Bisphosphonates), classified under Metabolic Bone Disease Agents

Metabolic Bone Disease Agents are a category of pharmaceutical active pharmaceutical ingredients (APIs) that are specifically designed to treat and manage conditions related to the bones and their metabolism. These agents play a crucial role in the treatment of various metabolic bone diseases, including osteoporosis, Paget's disease, and rickets.

The primary function of Metabolic Bone Disease Agents is to regulate bone remodeling and maintain bone health. They achieve this by targeting specific pathways involved in bone metabolism, such as osteoclast and osteoblast activity, calcium regulation, and vitamin D metabolism.

These APIs are commonly used in the development of medications, including oral tablets, injectables, and topical formulations, for the effective treatment of metabolic bone diseases. They are carefully formulated to optimize their pharmacokinetic and pharmacodynamic properties, ensuring maximum efficacy and minimal side effects.

Metabolic Bone Disease Agents encompass a range of substances, including bisphosphonates, selective estrogen receptor modulators (SERMs), calcitonin, and vitamin D analogs. These APIs act through different mechanisms to address specific aspects of bone health, such as inhibiting bone resorption, promoting bone formation, or regulating calcium levels.

In conclusion, Metabolic Bone Disease Agents are a vital category of pharmaceutical APIs used in the development of medications for the treatment and management of various metabolic bone diseases. These agents target specific pathways involved in bone metabolism to regulate bone remodeling, enhance bone health, and alleviate the symptoms associated with these conditions.

• LGM Pharma from United States, product country of origin World
• Teva API from Israel, product country of origin Unknown
• Alchymars ICM SM from India, product country of origin India
• JPN Pharma from India, product country of origin India
• Ind-Swift Labs. from India, product country of origin India
• Cipla from India, product country of origin Unknown
• Hetero Drugs from India, product country of origin India
• Ipca Labs. from India, product country of origin India
• Mylan from India, product country of origin India
• Sun Pharma from India, product country of origin India

Let the supplier know whether you are looking for a product with a specific monograph such as EP (Ph. Eur.), USP, JP, BP or another quality. Or, whether you are looking for hydrochloride (HCl), anhydricum, base, micronisatum or a specific purity.

You can use the filters to find high-quality suppliers. For example, you can select GMP, FDA or ISO certified suppliers. Visit our FAQ page or use the chat box in the corner to get more information about Pharmaoffer.